Prosecution Insights
Last updated: April 19, 2026
Application No. 18/477,748

TRANSLUCENT COSMETIC COMPOSITION

Non-Final OA §103
Filed
Sep 29, 2023
Examiner
MACH, ANDRE
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Amorepacific Corporation
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allow Rate
28 granted / 64 resolved
-16.2% vs TC avg
Strong +60% interview lift
Without
With
+60.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
49 currently pending
Career history
113
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
63.4%
+23.4% vs TC avg
§102
9.3%
-30.7% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 64 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Summary Receipt of Applicant’s disclosers filed on 09/29/2023 is acknowledged. Claims 1-12 are pending and under examination in this application. Priority The current application filed on 09/29/2023 claims priority to Korean patent application No. 10-2023-0003604 filed on 01/10/2023. Information Disclosure Statement The information disclosure statement (IDS) submitted on 09/29/2023 are in compliance with the provisions of 37 CFR 1.98. Accordingly, the information disclosure statements has been considered by the examiner. Signed copies have been attached to this office action. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-12 are rejected under 35 U.S.C. 103 as being unpatentable over Sun (KR 20140123295 A) in view of Morley (US 2011/0158920 A1). Sun teaches a cosmetic composition containing a transparent ceramide emulsion prepared by using ceramide, lecithin, heavy chain triglyceride, glycerin, water and an anionic surfactant, wherein the transparent ceramide emulsion has a small ceramide particle size, improves the skin barrier function, and strengthens the skin moisturizing power by reducing the amount of water-loss of the hard-skin surface (abstract). Regarding claims 1, 2, 3, 8 and 10, Sun teaches a transparent ceramide emulsion comprising 0.1 to 5% by weight of ceramide, from 0.01 to 5% by weight of lecithin, from 1 to 15% by weight of heavy chain triglyceride, from 1 to 50% by weight of glycerin, from 30 to 70%, 0.01 to 5% by weight of the cosmetic composition (¶ 0008). Moreover, Sun explicitly teaches ceramide NP (ceramide 3B) (¶ 0040 and 0002-0003). Furthermore, Sun discloses in Examples 1 and 2 and in formulation tables that triglyceride is kept at 1.0 wt %, and from 1 to 15 wt % of heavy chain triglyceride (claim 3). Regarding claim 5, Sun teaches 0.1 to 5 wt % of ceramide in the transparent cosmetic composition, and in Example 3, ceramide concentration is at 0.5 wt % in order to maintain in the “transparent” result (¶ 0054-0056). Regarding claim 6, Sun teaches in Examples 1 and 2, explicitly utilizes an oil phase caprylic/capric triglyceride at 1 wt % to maintain a “transparent” state. Regarding claim 7, Sun teaches the gelling agents used to stabilize the transparent ceramide emulsion are typically conventional water-soluble polymers, for example, Sun discloses cellulose derivative, microcrystalline cellulose (¶ 0008), and use of Carbopol (a well known carbomer) (¶ 0078) as a standard means to achieve the desired viscosity for a cosmetic product while maintaining the transparency of the ceramide particles. The gelling agents in Sun’s composition differs from applicant’s ethyl cellulose complex, however the general teaching and the use of a cellulose-based polymer gelling agent in a translucent cosmetic composition for stabilizing ceramide is taught and it would have been obvious a PHOSITA through routine substitution, in selecting a specific commercial blend like isostearoyl alcohol*butylene glycol cocoate*ethyl cellulose in order to optimize to the “gel cream” texture. Regarding claim 9, Sun teaches hydrogenated lecithin (saturated lecithin) (¶ 0038-0039). Regarding claim 11, Sun teaches caprylic/capric triglyceride (¶ 0056, 0078). Regarding claim 12, Sun teaches emulsified gel cream formulation (¶ 0008-2th ¶ and claim 6). Sun fails to specifically teach individual ratios of ceramide, gelling agent, lecithin and oil as claimed. Morley teaches a method for producing a bigel, the method comprising: (a) providing an oleogel comprising at least one oily agent gelled with at least one cellulose polymer; (b) providing an aqueous gel comprising at least one component whose Viscosity is pH dependent, such as a carbomer; (c) mixing the oleogel and the aqueous gel together to form a bigel; and (d) Subsequently adjusting the viscosity of the bigel under high flow and low shear stirring to obtain a bigel of a desired Viscosity (abstract). Regarding claims 4 and 5, Morley teaches providing an oleogel comprising at least one oily agent gelled with at least one cellulose polymer (¶ 0012), and the cellulose polymer may be chosen from ethyl cellulose, non-sodium carboxy-methylcellulose, and mixtures thereof (¶ 0026), ethyl cellulose is present in a proportion of between about 0.01 and 5 %, 0.1 and 10 % (¶ 0031-0032), and is well known in the art, the level of gelling provided by ethyl cellulose in the oleogel, and hence its viscosity, depends upon both the proportion and the grade of the ethyl cellulose (¶ 0033). Moreover, Morley discloses in one specific embodiment, the oily phase comprises ethyl cellulose in a proportion of between about 1 and about 10% by weight (¶ 0034), and suggests higher wt % to ensure stability (¶ 0035-0044). Therefore, the limitation of gelling agent greater than or equal to about 1 wt% is taught. Regarding claim 6, Morley teaches the preparation of bigels where the oil phase is gelled by a polymer, and that the ratio of gelling agent to the oil phase must be sufficient to trap the oil within the poly matrix, and for ethyl cellulose, it typically requires the polymer concentration to be equal to or greater than the oil concentration when the total oil phase is small, around 1%) (¶ 0054-0070). Regarding claim 7, Morley teaches as is well known in the art, the level of gelling provided by ethyl cellulose in the oleogel, and hence its viscosity, depends upon both the proportion and the grade of the ethyl cellulose. For a given amount by weight of ethyl cellulose in an oleogel, the higher the grade of ethyl cellulose used, the higher the viscosity of the oleogel. In other words, higher amounts of ethyl cellulose will generally be used when the grade of the ethyl cellulose is lower (¶ 0033) and to adjust the viscosity, suitable components include carbomers, and/or sodium carboxyl-methylcellulose (¶ 0053), and Carbomer is a generic name for a family of polymers known as Carbopols ® (¶ 0054). As noted in view of prior art Sun above, it would have been obvious a PHOSITA through routine substitution, in selecting a specific commercial blend like isostearoyl alcohol*butylene glycol cocoate*ethyl cellulose in order to optimize to the “gel cream” texture. It would have been prima facie obvious to a person having ordinary skill in the art (PHOSITA) before the effective filing date of the claimed invention to arrive at the claimed translucent composition by modifying Sun’s transparent ceramide cosmetic composition by optimizing and adjusting the ratios of the claimed ceramide, gelling agent, lecithin and oil to achieve the “translucent gel cream” cosmetic composition. Sun teaches a clear baseline for achieving a translucent appearance by utilizing a specific lipid ratio of ceramide, lecithin, and oil and maintaining nano-sized droplets formulation. However, Sun fails to teach the technical “feel” and lightness of a modern skincare product. Morley teaches the technical solution of utilizing ethyl cellulose-based gelling agents to transform liquid lipid phases into stable, semi-solid gel creams and thus It would have been reasonably obvious to combine Sun in view of Morley and a PHOSITA would have been motivated to combine the known cosmetic ingredients (ceramide, lecithin and triglycerides) and optimize the structure using standard cellulosic polymer. The resulting ratios (gelling agent greater or equal to ceramide and gelling agent greater or equal to oil) are the predictable outcome of combining the minimum polymer concentration required for gelation (1 wt %) as taught by Morley with the maximum oil/lipid concentration allowed for translucency (1 wt %) as taught by Sun. Moreover, It would have been prima facie obvious to a PHOSTA to combine the references because of known elements and methods to yield predictable results. As noted in the rejections above, Sun explicitly teaches ceramide NP (ceramide 3), hydrogenated lecithin, and caprylic/capric triglyceride as the optimal combination for transparent skin barrier product. The claimed ranges (0.5-1.0 wt % ceramide and ≤ 1 wt % oil) are explicitly disclosed as the “ideal” working embodiments in Sun for achieving “translucency”. Moreover, the addition of the specific ethyl cellulose gelling agent as taught by Morley to the emulsion of Sun to create a “gel cream” is a routine formulation modification choice to improve the product’s shelf-stability and sensory profile. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDRE MACH whose telephone number is (571)272-2755. The examiner can normally be reached 0800 - 1700 M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached at 571-272-0323. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDRE MACH/Examiner, Art Unit 1615 /Robert A Wax/Supervisory Patent Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Sep 29, 2023
Application Filed
Feb 18, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589072
BIOADHESIVE FILM AND METHODS OF USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12576072
LIQUID PHARMACEUTICAL COMPOSITION
2y 5m to grant Granted Mar 17, 2026
Patent 12564561
DILUTE READY TO USE LARGE VOLUME CONTAINERS OF PHENYLEPHRINE
2y 5m to grant Granted Mar 03, 2026
Patent 12564555
Continuous Processes for Manufacturing Impregnated Porous Carriers and for Manufacturing Pharmaceuticals Containing Impregnated Porous Carriers
2y 5m to grant Granted Mar 03, 2026
Patent 12508408
CHITOSAN POROUS STRUCTURE-BASED MAGNETICALLY ACTUATED MICROROBOT
2y 5m to grant Granted Dec 30, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
99%
With Interview (+60.0%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 64 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month